Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristy Gierke

Physician Assistant, Medical Savannah, GA Physician Assistant

NPI 1477902377 CMS profile 10853515

1601 Abercorn St, Savannah, GA 31401

Open in the dashboard

General payments

$10,767

589 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristy Gierke of Savannah, GA is reported in the CMS Open Payments database as having received $10,767 across 589 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,028 98
2024 General $2,557 122
2023 General $2,328 138
2022 General $1,718 101
2021 General $2,136 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristy Gierke
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kristy Gierke were reported at $2,028. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kristy Gierke Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,136 $156 $41–$563 $132
2022 $1,718 $185 $55–$649 $149
2023 $2,328 $199 $58–$717 $160
2024 $2,557 $206 $62–$740 $164
2025 $2,028 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,035 158 payments
  2. Otsuka America Pharmaceutical, Inc. $976 46 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $936 43 payments
  4. Axsome Therapeutics, Inc. $699 33 payments
  5. Supernus Pharmaceuticals, Inc. $622 26 payments
  6. Corium, Inc. $577 34 payments
  7. ITI, Inc. $536 25 payments
  8. Alkermes, Inc. $489 24 payments
  9. Neurocrine Biosciences, Inc. $334 16 payments
  10. Neos Therapeutics, LP $319 22 payments
  11. Other $3,243 162 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,767 589 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,552 128 payments
  2. TRINTELLIX $911 42 payments
  3. REXULTI $842 40 payments
  4. Azstarys $577 34 payments
  5. Auvelity $523 26 payments
  6. VRAYLAR Neuroscience $484 30 payments
  7. LYBALVI $438 21 payments
  8. ARISTADA Cns $438 21 payments
  9. ARISTADA Cns $438 21 payments
  10. Qelbree $420 11 payments
  11. Other $6,000 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

681

Median for Physician Assistant: 241

Drug cost

$43,999

Median for Physician Assistant: $4,110

Branded share of claims

21.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 14 $36,924
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 49 $1,633
Bupropion Xl Bupropion Hcl Brand 60 $877
Aripiprazole Generic 24 $644
Duloxetine Hcl Generic 38 $619
Alprazolam Generic 102 $467
Escitalopram Oxalate Generic 40 $420
Venlafaxine Hcl Er Venlafaxine Hcl Brand 25 $366
Trazodone Hcl Generic 33 $336
Clonazepam Generic 43 $299

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $420
$420 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $420
$420 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $158
  • Lundbeck LLC $133
$292 14 —
ARISTADA
  • Alkermes, Inc. $149
$149 — —
Auvelity
  • Axsome Therapeutics, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

589 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record